DE60217090D1 - Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel - Google Patents

Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel

Info

Publication number
DE60217090D1
DE60217090D1 DE60217090T DE60217090T DE60217090D1 DE 60217090 D1 DE60217090 D1 DE 60217090D1 DE 60217090 T DE60217090 T DE 60217090T DE 60217090 T DE60217090 T DE 60217090T DE 60217090 D1 DE60217090 D1 DE 60217090D1
Authority
DE
Germany
Prior art keywords
diagnostic imaging
amyloid plaque
aggregation inhibitors
imaging products
plaque aggregation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217090T
Other languages
English (en)
Other versions
DE60217090T2 (de
Inventor
Hank F Kung
Mei-Ping Kung
Zhi-Ping Zhuang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of DE60217090D1 publication Critical patent/DE60217090D1/de
Publication of DE60217090T2 publication Critical patent/DE60217090T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0468—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22—Tin compounds
    • C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60217090T 2001-04-23 2002-04-23 Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel Expired - Lifetime DE60217090T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28528201P 2001-04-23 2001-04-23
US285282P 2001-04-23
PCT/US2002/012626 WO2002085903A2 (en) 2001-04-23 2002-04-23 Amyloid plaque aggregation inhibitors and diagnostic imaging agents

Publications (2)

Publication Number Publication Date
DE60217090D1 true DE60217090D1 (de) 2007-02-08
DE60217090T2 DE60217090T2 (de) 2007-07-12

Family

ID=23093574

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60217090T Expired - Lifetime DE60217090T2 (de) 2001-04-23 2002-04-23 Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel

Country Status (12)

Country Link
US (5) US6696039B2 (de)
EP (1) EP1381604B1 (de)
JP (1) JP4317955B2 (de)
KR (1) KR20040058111A (de)
CN (1) CN100422180C (de)
AT (1) ATE349446T1 (de)
AU (1) AU2002258915B2 (de)
CA (1) CA2444214A1 (de)
DE (1) DE60217090T2 (de)
ES (1) ES2274973T3 (de)
TW (1) TWI245764B (de)
WO (1) WO2002085903A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7544511B2 (en) * 1996-09-25 2009-06-09 Neuralstem Biopharmaceuticals Ltd. Stable neural stem cell line methods
GB0018473D0 (en) * 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
ES2536449T3 (es) * 2000-08-24 2015-05-25 University Of Pittsburgh Of The Commonwealth System Of Higher Education Derivados de tioflavina para uso en diagnosis de la enfermedad de Alzheimer
CN100422180C (zh) 2001-04-23 2008-10-01 宾夕法尼亚州大学理事会 淀粉样斑块聚集抑制剂和诊断成像剂
EP1474178A1 (de) * 2002-02-13 2004-11-10 Amersham plc Benzodiazolderivate zur in vivo abbildung von amyloiden ablagerungen
US20040185429A1 (en) * 2002-12-09 2004-09-23 Judith Kelleher-Andersson Method for discovering neurogenic agents
US8293488B2 (en) 2002-12-09 2012-10-23 Neuralstem, Inc. Method for screening neurogenic agents
AU2004206956A1 (en) * 2003-01-22 2004-08-05 The General Hospital Corporation Amyloid-binding, metal-chelating agents
CA2438032C (en) * 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
CN102532055B (zh) * 2003-03-14 2016-05-11 匹兹堡大学联邦制高等教育 苯并噻唑衍生物化合物、组合物及用途
GB0307855D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Organic compounds
EP1631561B1 (de) 2003-05-07 2010-08-18 General Electric Company Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
US8236282B2 (en) 2003-08-22 2012-08-07 University of Pittsburgh—of the Commonwealth System of Higher Education Benzothiazole derivative compounds, compositions and uses
US20050049487A1 (en) * 2003-08-26 2005-03-03 Johnson Bruce Fletcher Compounds and kits for preparing imaging agents and methods of imaging
US8257680B1 (en) 2004-02-24 2012-09-04 The General Hospital Corporation Catalytic radiofluorination
US9017724B2 (en) 2004-02-24 2015-04-28 The General Hospital Corporation Catalytic radiofluorination
JP5311739B2 (ja) * 2004-03-18 2013-10-09 サントリーホールディングス株式会社 放射性ラベル基を有する３−［３−（ベンゾイルアミド）ベンジルオキシ］アスパラギン酸誘導体とその製造方法
BRPI0512893B8 (pt) * 2004-07-02 2021-07-27 Univ Pittsburgh métodos de determinação da eficácia da terapia no tratamento da amiloidose e de identificação de paciente como prodrômico para doença associada com a deposição amilóide e respectivos compostos
JP2008505116A (ja) * 2004-07-02 2008-02-21 ユニバーシティー オブ ピッツバーグ アミロイド沈着を伴う疾患の前駆形態の診断方法
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
EP2913393B8 (de) 2004-11-17 2020-02-26 Seneca Biopharma, Inc. Transplantation menschlicher Nervenzellen zur Behandlung neurodegenerativer Erkrankungen
AU2006261917A1 (en) * 2005-06-24 2007-01-04 The Trustees Of The University Of Pennsylvania Radiolabeled-pegylation of ligands for use as imaging agents
US7666886B2 (en) * 2005-07-15 2010-02-23 The Regents Of The University Of California Compounds and methods for the diagnosis and treatment of amyloid associated diseases
EP1928237A4 (de) 2005-09-02 2011-03-09 Abbott Lab Neue heterocyclen auf imidazo-basis
US20080219922A1 (en) * 2005-09-12 2008-09-11 Goodman Mark M Alzheimer's Disease Imaging Agents
CA2627722A1 (en) † 2005-10-31 2007-06-21 Merck & Co., Inc. Cetp inhibitors
JP4738419B2 (ja) 2005-11-30 2011-08-03 富士フイルムＲｉファーマ株式会社 アミロイドの凝集及び／又は沈着に起因する疾患の診断薬及び治療薬
JPWO2007069565A1 (ja) * 2005-12-12 2009-05-21 小野薬品工業株式会社 二環式複素環化合物
WO2007078335A2 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of lta4h for treating inflammation
TW201018678A (en) 2006-01-27 2010-05-16 Astrazeneca Ab Novel heteroaryl substituted benzothiazoles
TW200803903A (en) * 2006-04-28 2008-01-16 Nihon Mediphysics Co Ltd Novel compound having affinity to amyloid
EP2023919A4 (de) * 2006-05-08 2010-12-22 Molecular Neuroimaging Llc Verbindungen und amyloid-sonden für therapie- und bildgebungszwecke
NZ573363A (en) 2006-05-19 2012-01-12 Nihon Mediphysics Co Ltd Compound having affinity for amyloid based on an imidazopyridine-phenyl skeleton
TW200813035A (en) 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
US8277777B2 (en) 2006-06-21 2012-10-02 Nihon Medi-Physics Co., Ltd. Compound having affinity for amyloid
JPWO2008056481A1 (ja) * 2006-11-09 2010-02-25 日本メジフィジックス株式会社 放射性画像診断剤
WO2008059714A1 (fr) * 2006-11-17 2008-05-22 Nihon Medi-Physics Co., Ltd. Composés inédits présentant une affinité pour la substance amyloïde
KR20090083414A (ko) 2006-11-30 2009-08-03 니혼 메디피직스 가부시키가이샤 신규 아밀로이드 친화성 화합물
BRPI0806621A2 (pt) * 2007-01-22 2011-09-13 Astrazeneca Ab composto, uso de um composto, composição farmacêutica, e, método in vivo para medir depósitos amilóides em um indivìduo
EP2119458B9 (de) 2007-02-13 2013-08-21 Nihon Medi-Physics Co., Ltd. Verfahren zur herstellung eines abbildungsmittels zur strahlendiagnose
EP1964840A1 (de) 2007-02-28 2008-09-03 sanofi-aventis Imidazo[1,2-a]pyridine und deren pharmazeutische Verwendung
WO2008108729A1 (en) * 2007-03-06 2008-09-12 Astrazeneca Ab Novel 2-heteroaryl substituted indoles 695
TW200901998A (en) 2007-03-06 2009-01-16 Astrazeneca Ab Novel 2-heteroaryl substituted benzothiophenes and benzofuranes
FR2913886B1 (fr) 2007-03-22 2012-03-02 Guerbet Sa Utilisation de nanoparticules metalliques dans le diagnostique de la maladie d'alzheimer
WO2008134618A2 (en) * 2007-04-27 2008-11-06 The General Hospital Corporation Novel imaging tracers for early detection and treatment of amyloid plaques caused by alzheimer's disease and related disorders
WO2009054496A1 (ja) 2007-10-24 2009-04-30 Nihon Medi-Physics Co., Ltd. 新規アミロイド親和性化合物
AU2008314871A1 (en) 2007-10-26 2009-04-30 Nihon Medi-Physics Co., Ltd. Novel compound having affinity for amyloid
CA2704137A1 (en) * 2007-10-30 2009-05-07 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
JPWO2009057575A1 (ja) * 2007-10-30 2011-03-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物の使用及び製造方法
US20100267952A1 (en) * 2007-10-30 2010-10-21 Nihon Medi-Physics Co., Ltd. Use of novel compound having affinity for amyloid, and process for production of the same
JPWO2009057578A1 (ja) * 2007-10-30 2011-03-10 日本メジフィジックス株式会社 新規アミロイド親和性化合物の使用及び製造方法
US20110046378A1 (en) 2008-02-14 2011-02-24 Siemens Medical Solutions Usa, Inc. Novel Imaging Agents for Detecting Neurological Dysfunction
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
US20100331676A1 (en) * 2008-02-27 2010-12-30 Avid Radiopharmaceuticals, Inc. Gamma probe detection of amyloid plaque using radiolabeled a-beta binding compounds
CN104974024B (zh) * 2008-03-21 2017-11-14 综合医院公司 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
JP5603855B2 (ja) * 2008-04-04 2014-10-08 アビッド レディオファーマシューティカルズ、インク． 神経変成疾患の放射性薬剤による画像化
US8409419B2 (en) 2008-05-21 2013-04-02 Paul R. Kruesi Conversion of carbon to hydrocarbons
WO2009146388A1 (en) 2008-05-28 2009-12-03 The Trustees Of Columbia University In The City Of New York Voxel-based methods for assessing subjects using positron emission tomography
KR20110017407A (ko) * 2008-05-30 2011-02-21 포스터 휠러 에너지아 오와이 순산소 연소에 의해 전력을 생성하는 방법과 시스템
AU2009260526A1 (en) * 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted indoles
US8530483B2 (en) 2008-05-30 2013-09-10 Merck Sharp & Dohme Corp. Substituted azabenzoxazoles
US8420052B2 (en) 2008-07-24 2013-04-16 Siemens Medical Solutions Usa, Inc. Imaging agents useful for identifying AD pathology
EP2910945B1 (de) * 2008-09-30 2018-07-18 Case Western Reserve University Molekularsonden zur Bildgebung von Myelin
JP2012508889A (ja) * 2008-11-13 2012-04-12 アビッド レディオファーマシューティカルズ、インク． 神経変性疾患の検出と診断のためのヒストグラムに基づいた分析方法
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
EP2218464A1 (de) * 2009-02-11 2010-08-18 Technische Universität München Verbindungen zur nichtinvasiven Messung von Aggregaten von Amyloidpeptiden
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
CA2756137C (en) * 2009-03-23 2015-11-24 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
US8476449B2 (en) 2010-03-01 2013-07-02 Nihon Medi-Physics Co., Ltd. Radioactive iodine labeled organic compound or salt thereof
US9540611B2 (en) 2010-07-28 2017-01-10 Neuralstem, Inc. Methods for treating and/or reversing neurodegenerative diseases and/or disorders
EP2627361B1 (de) 2010-10-12 2017-09-20 Mayo Foundation For Medical Education And Research Abbildung von meningiomen mit phenylbenzothiazol-, stilben- oder biphenylalkynderivaten
RU2013125326A (ru) * 2010-11-16 2014-12-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Гетероциклические соединения в качестве зондов для визуализации tau-патологии
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
WO2012161116A1 (ja) 2011-05-20 2012-11-29 日本メジフィジックス株式会社 新規アミロイド親和性化合物
CN103596950B (zh) 2011-06-24 2017-12-19 日本医事物理股份有限公司 对淀粉状蛋白具有亲和性的化合物
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
WO2013082508A1 (en) * 2011-12-02 2013-06-06 The Regents Of The University Of Michigan Compositions and methods for the treatment and analysis of neurological disorders
WO2014004664A2 (en) 2012-06-27 2014-01-03 Mayo Foundation For Medical Education And Research Treatment of meningiomas using phenylbenzothiazole, stilbene, biphenylalkyne, or pyridine derivatives
EP3563849A3 (de) 2012-10-25 2020-02-12 The General Hospital Corporation Kombinationstherapien zur behandlung von morbus alzheimer und verwandten erkrankungen
US10058530B2 (en) 2012-10-25 2018-08-28 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
CN103073520B (zh) * 2012-12-24 2014-10-08 湖南大学 一种合成2-苯基苯并噻唑及其衍生物的方法
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
JP2016514091A (ja) 2013-02-08 2016-05-19 ミスフォールディング ダイアグノスティクス， インコーポレイテッド トランスサイレチン抗体およびその使用
PL2991983T3 (pl) 2013-04-29 2017-07-31 F.Hoffmann-La Roche Ag Pochodne 2-fenylo lub 2-hetaryloimidazolo[1,2-a]pirydyny
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP3049411B1 (de) 2013-09-26 2017-04-26 F. Hoffmann-La Roche AG Imidazo-[1,2-a-]pyridin-7-amine als bildgebungshilfsmittel
CA2928028A1 (en) 2013-10-22 2015-04-30 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2016064737A1 (en) 2014-10-20 2016-04-28 Neuralstem, Inc. Stable neural stem cells comprising an exogenous polynucleotide coding for a growth factor and methods of use thereof
EP3384960B1 (de) * 2015-12-30 2019-06-05 Neuboron Medtech Ltd. Neutroneneinfangtherapiesystem zur beseitigung von amyloid-beta-protein
CN108395446B (zh) * 2015-12-30 2020-02-28 南京中硼联康医疗科技有限公司 和β淀粉样蛋白特异性结合的化合物的制备方法
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
AU2017423862A1 (en) 2017-07-20 2020-02-06 Aztherapies, Inc. Powdered formulations of cromolyn sodium and ibuprofen
JP6831802B2 (ja) * 2018-01-12 2021-02-17 上海富吉医療器械有限公司Ｓｈａｎｇｈａｉ Ｃｈａｒｔｗｅｌｌ Ｍｅｄｉｃａｌ Ｉｎｓｔｒｕｍｅｎｔ Ｃｏ．， Ｌｔｄ． 放射性核種標識化合物及びこれを含有するイメージング剤
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
AU2019299347A1 (en) 2018-07-02 2021-01-21 Aztherapies, Inc. Powdered formulations of cromolyn sodium and alpha-lactose
KR102240400B1 (ko) * 2020-11-19 2021-04-15 한국원자력연구원 베타-아밀로이드 검출용 수용성 화합물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9317949D0 (en) 1993-08-28 1993-10-13 Stevens Malcolm F G Benzothiazole compounds
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US6168776B1 (en) 1994-07-19 2001-01-02 University Of Pittsburgh Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US6417178B1 (en) 1994-07-19 2002-07-09 University Of Pittsburgh Amyloid binding nitrogen-linked compounds for the antemortem diagnosis of alzheimer's disease, in vivo imaging and prevention of amyloid deposits
US6054114A (en) * 1996-05-08 2000-04-25 Massachusetts Institute Of Technology Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro
AU4988997A (en) 1996-10-23 1998-05-15 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US5869500A (en) 1996-12-13 1999-02-09 Hoffmann-La Roche Inc. Pyridone compounds useful in treating Alzheimer's disease
US6037473A (en) 1997-11-13 2000-03-14 Haarmann & Reimer Gmbh Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation
CN100422180C (zh) * 2001-04-23 2008-10-01 宾夕法尼亚州大学理事会 淀粉样斑块聚集抑制剂和诊断成像剂

Also Published As

Publication number Publication date
CN100422180C (zh) 2008-10-01
TWI245764B (en) 2005-12-21
ES2274973T3 (es) 2007-06-01
DE60217090T2 (de) 2007-07-12
JP2005512945A (ja) 2005-05-12
EP1381604B1 (de) 2006-12-27
US6696039B2 (en) 2004-02-24
AU2002258915B2 (en) 2007-11-15
USRE44338E1 (en) 2013-07-02
KR20040058111A (ko) 2004-07-03
JP4317955B2 (ja) 2009-08-19
US20060051293A1 (en) 2006-03-09
US20030059369A1 (en) 2003-03-27
ATE349446T1 (de) 2007-01-15
US20040131545A1 (en) 2004-07-08
EP1381604A2 (de) 2004-01-21
WO2002085903A3 (en) 2003-02-27
CN1620454A (zh) 2005-05-25
US7425318B2 (en) 2008-09-16
WO2002085903A2 (en) 2002-10-31
US6946116B2 (en) 2005-09-20
CA2444214A1 (en) 2002-10-31
USRE44354E1 (en) 2013-07-09

Similar Documents

Publication Publication Date Title
DE60217090D1 (de) Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel
HK1110313A1 (en) Stilbene derivatives and their use for binding and imaging amyloid plaques
MX2007007380A (es) Derivados de estilbeno y su uso para estudios de union y por imagenes de placas amiloides.
LU92232I2 (fr) "Florbétapir (18 F)"
WO2006078384A3 (en) Stilbene derivatives and their use
HUP0204074A2 (hu) Abéta peptidet kiválasztó humanizált ellenanyagok
NO20045434L (no) En kombinasjon av en NMDA-antagonist og acetylkolinesteraseinhibitorer for behandlingen av Alzheimers sykdom
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
IS8071A (is) Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
CY1107383T1 (el) Αναστολεις της φωσφολιπασης α2 του κυτοπλασμικου διαλυματος
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
NO20052888L (no) Diamintriazoler anvendelige som inhibitorer av proteinkinaser
MXPA04008068A (es) Metodo para administrar moleculas de glp-1.
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
BRPI0411743A (pt) método e composições para tratar doenças relacionadas a amilóides
WO2007033080A3 (en) Alzheimer's disease imaging agents
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
NO20030724L (no) Anvendelse av derivater av valproinsyreamider og 2- valproensyreamider for terapi eller prevensjon av smerte- og/eller hodepinelidelser
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
MXPA03007413A (es) Composicion y metodo para tratar enfermedades inflamatorias.
NO20025124D0 (no) Metode
DE60130659D1 (de) Therapeutische verbindungen und verfahren
HUP0402061A2 (hu) Rosszindulatú daganatok kezelésére alkalmas, egy biszfoszfonát, egy COX-2 inhibitor és egy taxol kombinációját tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
8364 No opposition during term of opposition